立方制药(003020.SZ)：收到原料药上市申请受理通知书

Core Viewpoint - The company, Lifan Pharmaceutical, has received a notice of acceptance for the listing application of Finerenone raw material from the National Medical Products Administration, indicating progress in its product development pipeline [1] Group 1: Product Information - Finerenone is a novel, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) intended for use in adult patients with chronic kidney disease associated with type 2 diabetes, specifically for those with an estimated glomerular filtration rate (eGFR) between 25 to 75 ml/min/1.73m² and albuminuria [1] - The formulation aims to reduce the risk of sustained decline in eGFR and end-stage renal disease [1] Group 2: Market Context - The application pertains to a generic chemical raw material used in already marketed formulations within the country [1] - Among the companies that have registered this raw material, five have an "A" status, indicating approval for use in marketed formulations, while the rest are marked as "I," meaning they have not yet passed the joint review and approval with the formulations [1]